

The Physiological Action of Picolinic Acid in the Human Brain

R.S. Grant^{1,2}, S.E. Coggan¹ and G.A. Smythe²

¹School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney NSW, 2052. ²Australasian Research Institute, Sydney Adventist Hospital, 185 Fox Valley Rd., Wahroonga, NSW, 2076. ³Bioanalytical Mass Spectrometry Facility (BMSF), UNSW, Sydney, NSW 2052.

Abstract: Picolinic Acid is an endogenous metabolite of L-tryptophan (TRP) that has been reported to possess a wide range of neuroprotective, immunological, and anti-proliferative effects within the body. However the salient physiological function of this molecule is yet to be established. The synthesis of picolinic acid as a product of the kynurenine pathway (KP) suggests that, similar to other KP metabolites, picolinic acid may play a role in the pathogenesis of inflammatory disorders within the CNS and possibly other organs.

In this paper we review the limited body of literature dealing with the physiological actions of picolinic acid in the CNS and its associated synthesis via the kynurenine pathway in health and disease. Discrepancies and gaps in our current knowledge of picolinic acid are identified highlighting areas of research to promote a more complete understanding of its endogenous function in the brain.

Background

Picolinic Acid (PIC) is a six-member ring structure compound (Fig. 1) that has been detected in a variety of biological mediums including, cell culture supernatants, blood serum¹ cerebrospinal fluid (CSF),² human milk, pancreatic juice and intestinal homogenates.³

PIC is synthesised from L-tryptophan (TRP) via a sequent side branch of the kynurenine pathway (KP) involving enzymatic shunting of an aminocarboxysemialdehyde intermediate toward PIC over non-enzymatic synthesis of the neurotoxin quinolinic acid (QUIN) (Fig. 2). TRP catabolism via the KP reputedly accounts for greater than 95% of the daily TRP turnover in the CNS.⁴ While a clear understanding of the physiological role of various KP metabolites and overall pathway dynamics remains elusive, at least a portion of TRP is converted to the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD).^{5,6}

Alan Mehler⁷ was the first to postulate that PIC was a metabolic product of the KP. Having identified that an enzymatic reaction perturbed the formation of PIC away from the synthesis of QUIN, Mehler questioned whether; a) PIC was a normal metabolic product of TRP with some physiological function and b) PIC production had some effect on NAD synthesis. While research has confirmed that PIC is a metabolite of the KP and knowledge of other aspects of the pathway has grown considerably over recent years, the salient endogenous function of PIC remains elusive, with its effect on NAD metabolism and significance in the CNS yet to be determined.

Alterations in KP metabolism have been implicated in the pathophysiology of a variety of CNS inflammatory diseases including; Alzheimer's disease,⁸⁻¹⁰ Multiple Sclerosis,¹¹ Parkinson's,¹² Cerebral Malaria,¹³ Amyotrophic lateral sclerosis¹⁴ and HIV infection.¹⁵ It is therefore reasonable to consider whether changes in PIC levels also correlate with either cellular or clinical pathology in any of these conditions.

In this review we discuss the potential physiological action of PIC identified by previous studies and place these findings within the context of both relevance to physiological conditions and associated KP metabolism. Discrepancies and gaps in our current knowledge of PIC are identified and areas of research that may promote a more complete understanding of PIC's endogenous function are suggested.

Physical Properties of PIC

Picolinic acid is a six-membered ring structure and isomer of nicotinic acid, containing five carbon atoms a nitrogen and a carboxyl group at position 2.

Correspondence: R.S. Grant, School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney NSW, 2052. Tel: +612 93853742; Fax: +612 9487 9626. Email: r.grant@unsw.edu.au



Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the Creative Commons Attribution By licence. For further information go to: <http://creativecommons.org/licenses/by/3.0/>.




Figure 1. Chemical structures of the isomers Picolinic acid **a)** and Nicotinic acid **b)**.

A number of synonyms exist for picolinic acid including, Pyridine-2-carboxylic Acid; 2-Pyridinecarboxylic acid; o-Pyridinecarboxylic Acid and alpha-Pyridinecarboxylic Acid. As a pure crystal, PIC has a melting point at $\sim 137^\circ\text{C}$ and is soluble in water to 887 g/l. The partial molal volume of PIC at infinite dilution is 83.8 ml mole, calculated from the density of its aqueous solutions. The refractivity at infinite dilution is 31.9 ml mole. Picolinic acid exists mainly in the zwitterion form in solution and displays relatively high viscosities where a 48% solution has about the same viscosity as a 38% sucrose solution at the same temperature.¹⁶

The most widely researched physical characteristic of picolinic acid is its efficient chelator properties. Chelator activity for PIC was first reported by Weidel in 1879, where PIC was shown to efficiently chelate both copper and iron. Later Suzuki et al¹⁷ in 1957 reported its efficient chelation of a range of metals including Ni, Zn, Cd, Pb and Cu.

Capitalizing on its chelation properties PIC-metal complexes are now widely used as a means of introducing bioactive metals into biological systems. In particular, as the element chromium appears to play a role in carbohydrate and lipid metabolism, dietary supplementation with chromium picolinate has been advocated in type 2 diabetes.¹⁸ As chromium is not assimilated particularly well from the diet more effective absorption is achieved through the ingestion of a PIC-chromium chelate. Chromium picolinate [Cr(pic)(3)] supplementation reportedly has effects on blood glucose and lipid metabolism and body composition.¹⁸ In these formulations PIC is generally considered the non-active ingredient that

helps solubilise the metal through the formation of the chelate complex.

Biological Synthesis of Picolinic Acid

TRP can be metabolised through oxidative degradation via the kynurenine pathway (KP) to one of three main end products; kynurenic acid (KYNA), PIC and NAD (Fig. 2). The KP begins with the oxidative cleavage of the amino acid tryptophan by either of the two enzymes *indoleamine 2,3-dioxygenase* (IDO; EC 1.13.11.17) or *tryptophan 2,3-dioxygenase* also called *tryptophan pyrolase* (TDO; EC 1.13.11.11) to produce formylkynurenine (Fig. 2). Both IDO and TDO are haem-requiring enzymes and are considered rate limiting for this pathway.

TDO is found predominantly in mammalian liver and can be induced by a number of factors including fasting, glucocorticoids, hydrocortisone, L-tryptophan and nicotinic acid.^{19,20} In contrast IDO is found mainly in extrahepatic tissues including brain, placenta, spleen, lung, kidney, alimentary tract and epididymis.^{20,21} Unlike TDO, IDO does not contain an activating site for tryptophan analogues²² and is induced primarily by the proinflammatory cytokine IFN- γ . IDO also uses the reactive oxygen intermediate (ROI) superoxide as opposed to molecular oxygen as a cofactor.²² TDO also differs from IDO in regard to substrate specificity. TDO uses L-tryptophan exclusively as substrate whereas IDO can metabolise both L and D-tryptophan as well as serotonin and other related indoleamines.²³




Figure 2. The kynurenine pathway in the CNS.

In the process of PIC synthesis tryptophan is catabolised through kynurenine to 3-hydroxyanthranilic acid. This is then further acted upon by the enzyme *3-hydroxyanthranilic acid oxygenase* (3HAO; EC 1.13.11.6), an enzyme present in both cytosol and synaptosomal fractions²⁴ to produce the intermediate 2-amino-3-carboxymuconic semialdehyde (Fig. 2).

The rate limiting enzyme for PIC production *amino-β-carboxymuconate-semialdehyde-decarboxylase* (ACMSD; EC 4.1.1.45) will preferentially convert this intermediate to 2-aminomuconic semialdehyde with subsequent non-enzymatic conversion to picolinic acid.²⁵ Non enzymatic rearrangement of the intermediate occurs when ACMSD is saturated with substrate²⁶ allowing the production of quinolinic acid (QUIN). It has been suggested that under normal conditions these two pathways control equal flux.²⁷ ACMSD is therefore a key enzyme directing KP metabolism towards PIC production, and is expressed at a ratio of 1300 : 30 : 1 in kidney, liver and brain, respectively.²⁸ Not surprisingly the activity of ACMSD has been shown to be

inversely proportional to the amount of NAD synthesised from tryptophan.²⁵

Physiological Role of KP Metabolism

In the periphery, the role of the KP appears to be primarily directed toward the production of NAD, with other KP metabolites excreted unchanged in high concentrations in the urine.²⁹ In the CNS, however, the purpose of KP activation is less clear. Generation of NAD is integral to brain function and may be derived *de novo* from tryptophan.⁶ However, KP activation potentially occurs in all brain cell types, including neurons,¹⁰ astrocytes,³⁰ infiltrating macrophages,³¹ dendritic cells³² and blood brain barrier (BBB) endothelial cells.³³ With many kynurenines (the collective term for KP metabolites) showing neuro-modulatory function in the CNS it is unclear at what point synthesis and release of various kynurenines change from being part of normal physiological processes to becoming contributors to pathophysiological activity.

Quinolinic acid (QUIN) and KYNA are two neuroactive KP metabolites that have received considerable attention for their modulation of the excitatory amino acid N-methyl-D-aspartate (NMDA) receptor. While QUIN shows neurotoxic effects by over activation of the NMDA receptor, KYNA offers neuro-protection by blocking receptor function via an allosteric glycine site.³⁴ Emphasis has, therefore, been placed upon the importance of maintaining a balanced ratio between these two metabolites.

Often overlooked however, is the observation that PIC also shows antagonistic properties towards the toxic effects of QUIN via an unknown mechanism.^{35,36} PIC's role in maintaining the balance between neurotoxic and neuro-protective KP metabolites requires further investigation.

Experimental Actions of PIC:

In vitro and *In vivo*

On its own, in experimental systems, PIC is reported to elicit a number of potential effects within the body, particularly involving immune function and antimicrobial activity.

In vitro studies suggest that PIC (at supernatant concentrations of 1–4 mM) can enhance macrophage effector functions through the enhancement of interferon- γ (INF γ) dependant nitric oxide synthase (NOS) gene expression^{37,38} and induce expression of the macrophage inflammatory proteins (MIP)1 α and 1 β .³⁹ While the mechanism producing the synergism with INF- γ is not known PIC mediated induction of MIP 1 α and β is thought to be through an iron chelation dependant process.

High PIC concentrations (1–4 mM) have also been reported to selectively inhibit a variety of viruses in culture including the Human Immuno-deficiency virus (HIV), Herpes Simplex virus (HSV), and Simian virus (SV) in culture.^{40,41} PIC appears to produce its antiviral activity through an initial cytotoxic action which in turn increases apoptosis of infected cells and a reduction in viral replication.⁴¹ PIC in combination with IFN γ has also been shown to inhibit retroviral expression of the J2 retrovirus,⁴² again through an unknown mechanism.

Anti-microbial effects of PIC (2.5–40 mM) have been observed against *Mycobacterium avium* complex (MAC), with significant enhancement of the antimicrobial action of the drugs clarithromycin, rifampin and various fluoroquinolones.^{43,44} It is suggested that as PA efficiently chelates metal ions, such as Zn²⁺ and Fe²⁺ it is therefore likely that its antimicrobial activity against MAC organisms is due to its ability to chelate essential metal ions such as Fe²⁺.⁴³

Some investigators have also observed an effect of PIC on tumour growth. *In vivo* studies on mice inoculated with MBL-2 lymphoma cells showed that those treated with injections of PIC (100 mg/Kg) in combination with activated macrophages, had significant increases in lifespan compared to control.⁴⁵ These effects are arguably due to macrophage activation mechanisms through IFN- γ mediated mechanisms as suggested previously.⁴⁵

Importantly high concentrations of PIC, relative to physiological levels, were used in all of the investigations discussed above. Tables 1 and 2 highlight the large discrepancy between PIC concentrations used experimentally *in vitro/in vivo*

Table 1. PIC concentrations used experimentally.

Reported physiological effects of PIC	[PIC] used	Reference
Induces MIP 1 α & β expression ¹	4000 μ M	39
Enhances IFN- γ mediated NO production ¹	4000 μ M	37
Anti-tumour activity ²	100 mg/kg	45
Anti-viral: SV-transformed cells ¹	1000–3000 μ M	40
Anti-viral: HIV infected cells ¹	1500–3000 μ M	40
Anti-viral: J2 retrovirus ¹	4000 μ M	42
Anti-microbial: against MAC	2500–20000 μ M	43
complex ¹	2500–40000 μ M	44

Experiment performed using: ¹cell culture, ²whole animal (mouse).

Table 2. Endogenous concentrations of PIC.

Reported endogenous PIC locations	[PIC] (μM)	Reference
Plasma	0.299 $\pm$ 0.034	8
Brain (cortical tissue)	0.100–0.150	8
CSF (no brain injury)	0.017 $\pm$ 0.005	8

(Table 1) and reported levels of endogenous PIC (Table 2). With PIC concentrations *in vivo* generally ranging within the low to mid *nano* (10^{-9}) molar range the millimolar (10^{-3}) concentrations used in the above cited studies have generally resulted in an approximately one million fold difference between physiological and experimental PIC concentrations. While these studies do indicate possible therapeutic roles for PIC, the large discrepancy between endogenous and experimental PIC levels does raise a question over the relevance of these observations to the natural physiological function of PIC.

PIC Concentrations in Diseases of the CNS

An often useful aid to understanding the physiological role of an uncharacterised biological molecule is the study of changes in the endogenous levels of the molecule in health and disease. Current literature in this area is however limited to a report by Medana et al.¹³ showing raised PIC levels in the CSF of patients with cerebral malaria and a recent report from our own group in which no significant difference in PIC levels were identified between different CNS disease categories.⁴⁶ Importantly we have shown that any attempt at correlating PIC levels in the CNS may be complicated by an apparent diurnal fluctuation in CSF PIC levels as discussed later in this review.

As PIC is part of a more complex pathway, it is relevant to review how other kynurenines are affected by disease and under what conditions altered levels have been observed (for summary see Table 3).

It has been suggested that altered KP metabolism contributes significantly to the pathophysiology of neurodegenerative and inflammatory disorders of the CNS.³⁴ Lower levels of KYNA and the enzymes involved in its production have been found in the plasma, CSF and erythrocytes of Parkinson's and Alzheimer's disease sufferers.^{9,47,48}

On the other hand, Huntington's disease subjects exhibited elevated cortical QUIN levels in the early stages of disease onset, suggesting excitotoxicity as the cause of later neurodegeneration.⁴⁹

Various viral infections show an up regulation of the entire KP. HIV infection exhibits increased levels of both QUIN and TRP in the human brain,⁵⁰ while in the CSF, QUIN has been further correlated to worsening brain atrophy.⁵¹ Poliovirus infected macaques showed increases of CSF QUIN, KYNA, L-kynurenine, kynurenine-3-hydroxylase, and kynureninase activities, with the magnitude of increase correlating with the severity of observed motor deficits.⁵²

In a study of African children suffering from cerebral malaria elevated PIC and QUIN concentrations predicted a fatal outcome to the disease.¹³ These observations are consistent with results reported in an animal model using centrally infected (*Plasmodium berghei*) mice, where CSF PIC also increased markedly with malarial infection.⁵³

While some studies have shown that immune activation can result in elevated PIC levels^{37–39} a recent study by our group failed to find any correlation between CSF PIC concentrations and CNS disease states.⁴⁶ This data was generated from a population of 241 patients that were suspected of meningitis as well as other nervous system disorders. Immune activation markers such as white cell count and C-reactive protein also did not show any correlation with CSF PIC concentrations.

These results led us to investigate whether other biological factors may influence the production of PIC in the CNS.

Biological Factors Influencing PIC Levels in the CNS

We have recently reported that CSF PIC levels in the CNS may be influenced by both the age of the subject and time of sample collection.⁴⁶ This observation has not been previously reported, although other studies have noted similar patterns for other

Table 3. Altered Kynurenine pathway metabolites in disease.

CNS disease	Alteration of kynurenines in the CNS (CSF/brain tissue ^Ψ)			Reference
	QUIN	KYNA	PIC	
Alzheimer's	nt	nt	n/s ^Ψ	8
	nt	↓	nt	9
Parkinson's	nt	↓	nt	12
Multiple sclerosis	↑ ^Ψ	↓	nt	11
Huntington's	↑	nt	nt	49
Cerebral Malaria	↑	↑	↑	13
HIV infection	nt	↑	nt	52
Down Syndrome	nt	↑ ^Ψ	nt	72
Amyotrophic lateral sclerosis	nt	↑	nt	73
	↑	nt	nt	14

↑ = Elevated levels compared to control, ↓ = decreased levels compared to control.

Abbreviations: nt, not tested, n/s, not significant.

kynurenines. In a population without detectable neurological disease Kepplinger et al.⁵⁴ and Heyes et al.⁹ observed that CSF KYNA levels significantly increased with advancing age. Consistent with our observation, the activity of the PIC producing enzyme ACMSD has been shown to increase with age in studies of rat kidney, liver and small intestine.⁵⁵ Unfortunately, an investigation of age-associated changes in ACMSD activity in human tissue is yet to be reported.

From a sample of subjects with no apparent CNS disease, we observed that CSF PIC concentrations display a significant diurnal variation depending on the time of sample collection.⁴⁶ Importantly, QUIN levels did not show this diurnal pattern, thus making the observation unique to PIC alone and suggesting the diurnal variation in ACMSD activity is most likely caused by substrate availability. Further, this circadian fluctuation was not observed in CSF PIC levels from patients with apparent CNS disease, suggesting that this temporal rhythm in PIC concentrations can be significantly perturbed during times of immune activation.

This observed diurnal fluctuation is remarkably similar to a serial CSF sampling study of 12 healthy volunteers by Kennedy and colleagues.⁵⁶ A significant diurnal pattern in CSF TRP metabolism was observed, with low TRP levels at near noon, and a maximum reached at 11 pm—midnight.⁵⁶ From this, it was proposed that the peak to trough availability of TRP as a precursor molecule may

be of sufficient magnitude to influence other metabolite processes, such as melatonin secretion, which also follows a diurnal cycle.⁵⁶

With a diurnal fluctuation modelled by variations in TRP levels, it can be proposed that the availability of TRP in the CSF has a direct affect on substrate availability for CNS PIC production.

Future studies are required to establish what conditions affect the baseline diurnal fluctuation of CSF PIC and what pathophysiological/disease states may be linked to these changes.

Enzymatic Control of PIC Production: ACMSD

As the availability of substrate will impact the synthesis of PIC in the CNS,⁵⁶ it is relevant to consider whether the activity of surrounding metabolic enzymes could also influence PIC levels.

ACMSD activity will be influenced by the availability of its relevant substrate which in turn is dependant on flux through the KP. The activity of IDO, the rate limiting enzyme of the KP, (Fig. 2) is therefore positioned to significantly influence the synthesis of the PIC precursor.

IDO activity has been shown to be involved in a variety of physiological processes. IDO activation can influence maternal tolerance toward the allogenic fetus⁵⁷ regulate autoimmune disorders,⁵⁸ and suppress transplant rejection.⁵⁹ Inhibitors of this enzyme are, therefore, currently being developed for cancer immunotherapy.⁶⁰

While the mechanism through which IDO displays its immune activity appears to involve tryptophan concentrations in the microenvironment⁵⁷ the influence of downstream metabolites such as PIC on these and other activities has not been extensively investigated.

As ACMSD substrate required for PIC synthesis is dependant on IDO activity, any therapeutic manipulation of IDO will affect the synthesis of PIC. Understanding the pathophysiological role of PIC may help prevent potential PIC associated side effects following IDO inhibition.

The position of ACMSD within the KP establishes it as the rate limiting enzyme for PIC synthesis (Fig. 2). Interestingly, a number of nutritional factors and hormonal effects have been observed to alter the activity of this enzyme.

High protein diets, the diabetic condition⁶¹ and increased glucocorticoids⁶² have all been demonstrated to increase the activity of ACMSD. Whereas high levels of dietary polyunsaturated fatty acids,⁶³ peroxisome-proliferators⁶⁴ and the environmental plasticizer contaminants, phthalate esters⁶⁵ appear to significantly down-regulate the activity of this enzyme.

While the physiological rationale for these changes is not known, high protein diets have previously been shown to also increase enzymes associated with energy metabolism.⁶⁶ Is it possible that ACMSD/PIC may play a role in the regulation glucose/energy metabolism? It is relevant to note that a number of metalpicolinate complexes have been found with insulinomimetic activity where the presence of the picolinate significantly enhances the insulin sensitising activity.⁶⁷

Importantly most studies in this area have measured the activity of ACMSD from the peripheral tissue of animal models. Peripheral tissue data may or may not correlate substantially with the centrally located human protein which apparently has a relatively low level of expression.²⁸ The lack of relevant experimental data relating to the human CNS highlights the need for future research in this area.

PIC and the BBB

The measurement of PIC in the CSF is assumed to reflect endogenous PIC production within the CNS alone. However it is also possible that CSF levels may be influenced by transfer of PIC from the peripheral circulation.

Chromium picolinate is an established dietary supplement used to treat conditions of insulin resistance.¹⁸ The ability of this complex to produce affects within the CNS has been queried.⁶⁸ Aggett et al.⁶⁹ reported that divalent metal complexes of PIC do not readily pass through lipid bilayers. PIC itself also has a relatively low partition coefficient ($\log P = 0.098^a$) reflecting its low solubility in a lipophilic medium. This makes it unlikely that PIC would pass through the BBB on its own. In addition, Smythe and colleagues⁸ reported that PIC plasma levels were at concentrations 3–15 times higher than those in the brain tissue and CSF (Table 2). For such a concentration ratio to be maintained, it is thought that limited flux of PIC occurs between the CNS and the periphery.

While the above observations indicate that CSF PIC levels reflect PIC synthesis within the CNS, other KP metabolites may contribute significantly to their respective cerebral pools.

In experiments using *in situ* brain perfusion techniques on rats, L-kynurenine and 3-hydroxykynurenine were found to be taken up into the brain at significant rates across the BBB via the large amino acid transporter.⁷⁰ Owe-Young and colleagues³³ recently found that KP activation occurs in BBB endothelial cells, and when treated with $\text{INF}\gamma$, increased the expression of kynurenine but not QUIN or PIC. That these metabolites contribute to PIC production through increased substrate availability has been proposed but never tested.⁷¹ It would be beneficial to our understanding in this area if future studies examined the concentration of PIC in the CNS under conditions of both peripheral KP supplementation and peripheral KP activation.

In summary, there are a number of biological factors that can potentially affect PIC levels and synthesis in the CNS including; age and circadian rhythms and hormonal and nutritional factors.

However the physiological role(s) of PIC within the CNS is not well understood. Improved understanding may be achieved by characterizing the changes to cell/organ biochemistry/physiology at PIC concentrations within acceptable physiological concentrations. In addition, it has not been established whether there is a link between PIC concentration and any disease state. Whether PIC production is as clearly connected to

^aLog P calculated by Advanced Chemical Development log P Batch version 100 software.

pathophysiological changes as other kynurenines such as QUIN and KYNA requires further investigation with careful attention to the confounding effects of age and diurnal rhythm.

Disclosure

The authors report no conflicts of interest.

References

1. Dazzi, C, Candiano G, Massazza S, Ponzetto A, Varesio L. New high-performance liquid chromatographic method for the detection of picolinic acid in biological fluids. *J Chromatogr.* 2001;751:61–8.
2. Smythe GA, Braga O, Brew BJ, et al. Concurrent Quantification of Quinolinic, Picolinic, and Nicotinic Acids Using Electron-Capture Negative-Ion Gas Chromatography Mass Spectrometry. *Anal Biochem.* 2002;301:21–6.
3. Rebello T, Lonnerdal B, Hurley LS. Picolinic acid in milk, pancreatic juice, and intestine: inadequate for role in zinc absorption. *Am J Clin Nutr.* 1982;35:1–5.
4. Peters JC. Tryptophan nutrition and metabolism: an overview. *Adv Exp Med Biol.* 1991;294:345–58.
5. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for Increased de Novo Synthesis of NAD in Immune-Activated RAW264.7 Macrophages: A Self-Protective Mechanism? *Arch Biochem Biophys.* 1999;372:1–7.
6. Grant R, Kapoor V. Inhibition of indoleamine 2,3-dioxygenase activity in IFN- γ stimulated astroglia cells decreases intracellular NAD levels. *Biochem Pharmacol.* 2000;66:1033–6.
7. Mehler AH. Formation of picolinic and quinolinic acids following enzymatic oxidation of 3-hydroxyanthranilic acid. *J Biol Chem.* 1956;218(1):241–54.
8. Smythe GA, Poljak A, Bustamante S, et al. ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. *Adv Exp Med Biol.* 2003;527:705–12.
9. Heyes M, Saito K, Crowley J, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease. *Brain.* 1992;115:1249–73.
10. Guillemain GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. *Glia.* 2005;49:15–23.
11. Rejdak K, Bartosik-Psujek H, Dobosz B, et al. Decreased level of kynurenine acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. *Neurosci Lett.* 2002;4: 331(1):63–5.
12. Hartai Z, Juhasz A, Rimanoczy A, et al. Decreased serum and red blood cell kynurenine acid levels in Alzheimer's disease. *Neurochem Int.* 2007;50:308–13.
13. Medana IM, Day NPJ, Salahifar-Sabet H, et al. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. *J Infect Dis.* 2003;188: 844–9.
14. Guillemain GJ, Meininger V, Brew BJ. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. *Neurodegener Dis.* 2005;2:166–76.
15. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. *Ann Neurol.* 1991;29:202–9.
16. Robinson RA, Green RW. Some Physical Properties of Aqueous Picolinic Acid Solutions. *J Phys Chem.* 1961;65(6):1084.
17. Suzuki K, Yasuda M, Yamasaki K. Stability constants of picolinic and quinaldic acid chelates of bivalent metals. *J Phys Chem.* 1957;61: 229–31.
18. Broadhurst CL, Domenico P. Clinical studies on chromium picolinate supplementation in diabetes mellitus—a review. *Diabetes. Technol. Ther.* 2006;8:677–87.
19. Sainio E, Sainio P. Comparison of effects of Nicotinic acid or Tryptophan on tryptophan 2,3-dioxygenase in acute and chronic studies. *Toxicol Appl Pharmacol.* 1990;102:251–8.
20. Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. Regulation of indoleamine 2,3-dioxygenase activity in the small intestine and the epididymis of mice. *Archiv Biochem Biophys.* 1980;203: 343–51.
21. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indoleamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. *Biochem J.* 1985;230:635–8.
22. Botting NP. Chemistry and Neurochemistry of the Kynurenine pathway of Tryptophan metabolism. *Chemical Society Reviews* 1995;401–12.
23. Ishimura Y, Nozaki M, Hayaishi O. The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. *J Biol Chem.* 1970;245:3593–602.
24. Saito K, Markey SP, Heyes MP. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. *Neuroscience.* 1992;51:25–39.
25. Ikeda M, Tsuji S, Nakamura S, Ichijima A, Nishizuka Y, Hayaishi O. Studies on the biosynthesis of nicotinamide adenine dinucleotide. ii. A role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. *J Biol Chem.* 1965;240:1395–401.
26. Bender DA, McCreaner GM. Kynurenine hydroxylase: a potential rate limiting enzyme in tryptophan metabolism. *Biochemical Society Transactions.* 1985;13:441–3.
27. Salter M, Knowles RG, Pogson CI. Quantification of the importance of individual steps in the control of aromatic amino acid metabolism. *Biochem J.* 1986;234:635–47.
28. Pucci L, Perozzi S, Cimadamore F, Orsomando G, Raffaelli N. Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. *FEBS J.* 2007;274:827–40.
29. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. *J Pharmacol Exp Ther.* 2002;303:1–10.
30. Guillemain GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. *J Neurochem.* 2001;78: 842–53.
31. Heyes MP, Achim CL, Wiley CA, Major EO, Sato K, Markey SP. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. *Biochem J.* 1996;320:595–7.
32. Hwu P, Du MX, Lapointe R, Do M, Taylor M W, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. *J Immunol.* 2000;164:3596–9.
33. Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. *J Neurochem.* 2008;105:1346–57.
34. Jhamandas KH, Boegman RJ, Beninger RJ, Miranda AF, Lipic KA. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. *Neurotox Res.* 2000;2:139–155.
35. Beninger RJ, Colton AM, Ingles JL, Jhamandas K, Boegman RJ. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. *Neurosci Res.* 1994;61:603–12.
36. Cockhill J, Jhamandas K, Boegman RJ, Beninger RJ. Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage. *Brain Res.* 1992;599: 57–63.
37. Melillo G, Cox GW, Biragynn A, Sheffler LA, Varesiot L. Regulation of Nitric-oxide Synthase mRNA Expression by Interferon- γ and Picolinic Acid. *J Biol Chem.* 1994;269:8128–33.
38. Varesio L, Clayton M, Blasi E, Ruffman R, Radzioch D. Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN- γ -primed macrophages. *J Immunol.* 1990;145: 4265–71.

39. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1 α and -1 β in Macrophages. *J Immunol.* 2000;164:3283–91.
40. Fernandez-Pol JA, Johnson GS. Selective toxicity induced by picolinic acid in simian virus 40-transformed cells in tissue culture. *Cancer Res.* 1977;37:4276–9.
41. Fernandez-Pol JA, Klos DJ, Hamilton PD. Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. *Anticancer Res.* 2001;21:3773–6.
42. Blasi E, Radzioch D, Varesio L. Inhibition of Retroviral mRNA expression in the murine macrophage cell line GG2EE by biological response modifiers. *J Immunol.* 1988;141:2153–7.
43. Cai S, Sato K, Shimizu T, Yamabe S, Hiraki M, Sano C, Tomioka H. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones. *J Antimicrob Chemother.* 2006;57:85–93.
44. Shimizu T, Tomioka H. Activity of Picolinic Acid in Combination with the Antiprotozoal Drug Quinacrine against Mycobacterium avium Complex. *Antimicrob Agents Chemother.* 2006;50:3186–8.
45. Ruffman R, Schlick R, Chirigos MA, Budzynsky W, Varesio, L. Antiproliferative activity of picolinic acid due to macrophage activation. *Drugs Exp Clin Res.* 1987;13:604–14.
46. Coggan SE, Smythe GA, Bilgin A, Grant RS. Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. *J Neurochem.* 2009;08:1220–5.
47. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. *J Neurol Sci.* 2005b;239:31–5.
48. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. *Acta Neurol Scand.* 2005a;112:93–6.
49. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinic levels are increased in early grade Huntington's disease. *Neurobiol Dis.* 2004;17:455–61.
50. Brown R, Ozaki S, Datta S, Borden E, Sondel P, Malone D. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. *Adv Exp Med Biol.* 1991;294:425–35.
51. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fluid quinolinic acid levels are associated with region-specific cerebral volume loss in HIV infection. *Brain.* 2001;124:1033–1042.
52. Heyes MP, Saito K, Major EO, Milstien SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. *Brain Res.* 1993;116(Pt 6):1425–50.
53. Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, Phillips RS. () Prolonged Survival of a Murine Model of Cerebral Malaria by Kynurenine Pathway Inhibition. *Infect Immun.* 2005;73:5249–51.
54. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. Age-related increase of kynurenine acid in human cerebrospinal fluid—IgG and beta2-microglobulin changes. *Neurosignals.* 2005;14(3):126–35.
55. Comai S, Costa CVL, Ragazzi E, Bertazzo A, Allegri G. The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. *Clin Chim Acta.* 2005;360:67–80.
56. Kennedy JS, Gwirtsman HE, Schmidt DE, et al. Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. *Life Sci.* 2002;71:1703–15.
57. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science* 1998;281:1191–3.
58. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. *Faseb J.* 2005;19:1347–9.
59. Uyttenhove C, Pilotte L, Theate I, et al. () Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat Med.* 2003;9:1269–74.
60. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. *Cancer Res.* 2007;67:792–801.
61. Tanabe A, Egashira Y, Fukuoka S, et al. Expression of rat hepatic 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase is affected by a high protein diet and by streptozotocin-induced diabetes. *J Nutr.* 2002;132:1153–9.
62. Egashira Y, Murotani G, Tanabe A, et al. Differential effects of dietary fatty acids on rat liver alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase activity and gene expression. *Biochim Biophys Acta.* 2004;1686:118–24.
63. Egashira Y, Ogawara R, Ohta T, Sanada H. Suppression of rat hepatic a-amino-b-carboxymuconate- e-semialdehyde decarboxylase (ACMSD) activity by linoleic acid in relation to its induction by glucocorticoids and dietary protein. *Biosci Biotech Biochem.* 1994;58.
64. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD⁺ pathway. *Toxicol Appl Pharmacol.* 1999;158:71–80.
65. Fukuwatari T, Ohsaki S, Fukuoka S, Sasaki R, Shibata K. Phthalate Esters Enhance Quinolinic Production by Inhibiting Amino- β -Carboxymuconate-Semialdehyde Decarboxylase (ACMSD), a Key Enzyme of the Tryptophan Pathway. *Toxicol Sci.* 2004;81: 302–308.
66. Szepesi B, Freedland RA. Time-course of changes in rat liver enzyme activities after initiation of a high protein regimen. *J Nutr.* 1968;94(4): 463–468.
67. Yasumatsu N, Yoshikawa Y, Adachi Y, Sakurai H Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metal-lopicolinate complexes. *Bioorg Med Chem.* 2007;15(14):4917–22.
68. Reading SA. Chromium picolinate. *J Fla Med Assoc.* 1996; 83:29–31.
69. Aggett, P J, Fenwick PK, Kirk H. An In Vitro Study of the Effect of Picolinic Acid on Metal Translocation across Lipid Bilayers. *J Nutr.* 1989;119:1432–7.
70. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. *J Neurochem.* 1991;56:2007–2017.
71. Stone TW. Neuropharmacology of quinolinic acids and kynurenine acids. *Pharmacol Rev.* 1993;45:309–79.
72. Baran H, Cairns N, Lubec B, Lubec G. Increased kynurenine acid levels and decreased brain kynurenine aminotransferase in patients with downs syndrome. *Life Sci.* 1996;58:1891–9.
73. Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenine acid in amyotrophic lateral sclerosis. *Acta Neurol Scand.* 2003;107:412–8.